Cargando…

Use of sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations

Diabetes mellitus in Asia accounts for more than half of the global prevalence. There is a high prevalence of cardiovascular disease (CVD) in the region among people with type 2 diabetes mellitus (T2DM) and it is often associated with multiple risk factors including hypertension, renal disease and o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deerochanawong, Chaicharn, Chan, Siew P., Matawaran, Bien J., Sheu, Wayne H.‐H., Chan, Juliana, Man, Nguyen H., Suastika, Ketut, Khoo, Chin M., Yoon, Kun‐Ho, Luk, Andrea, Mithal, Ambrish, Linong, Ji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852284/ https://www.ncbi.nlm.nih.gov/pubmed/31264765 http://dx.doi.org/10.1111/dom.13819

Ejemplares similares

Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
por: Sheu, Wayne Huey-Herng, et al.
Publicado: (2020)

Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations
por: Khoo, Chin Meng, et al.
Publicado: (2020)

Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes
por: Tan, Jack Wei Chieh, et al.
Publicado: (2021)

Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East
por: Alshamiri, Mostafa, et al.
Publicado: (2018)

Device-supported automated basal insulin titration in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
por: Luo, Yingying, et al.
Publicado: (2023)

Use of basal insulin in the management of adults with type 2 diabetes: An Asia‐Pacific evidence‐based clinical practice guideline
por: Ji, Linong, et al.
Publicado: (2023)

Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta‐analysis
por: Luo, Yingying, et al.
Publicado: (2023)

Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review
por: Sheu, Wayne H‐H, et al.
Publicado: (2017)

Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register
por: Lim, Lee‐Ling, et al.
Publicado: (2022)

Expert Consensus Recommendations on Time in Range for Monitoring Glucose Levels in People with Diabetes: An Indian Perspective
por: Mohan, Viswanathan, et al.
Publicado: (2023)

Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective
por: Ji, Linong, et al.
Publicado: (2020)

AFES A.S.-O.N.E.: ASEAN Survey Of Needs in Endocrinology in the Time of the COVID-19 Pandemic
por: Jasul, Gabriel, et al.
Publicado: (2020)

Diabetes management in Thailand: a literature review of the burden, costs, and outcomes
por: Deerochanawong, Chaicharn, et al.
Publicado: (2013)

Basal Insulin Dose Titration for Glycemic Control in Patients With Type 2 Diabetes Mellitus in Thailand: Results of the REWARDS Real-World Study
por: Deerochanawong, Chaicharn, et al.
Publicado: (2020)

Choice of Insulin in Type 2 Diabetes: A Southeast Asian Perspective
por: Kalra, Sanjay, et al.
Publicado: (2017)

Forum for Injection Technique and Therapy Expert Recommendations, India: The Indian Recommendations for Best Practice in Insulin Injection Technique, 2017
por: Tandon, Nikhil, et al.
Publicado: (2017)

The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus
por: Lastya, Agus, et al.
Publicado: (2014)

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2019)

Predictors of Poor Glycemic Control and Increased Glucose Variability Among Admitted Moderate to Critical COVID-19 Patients with Type 2 Diabetes Mellitus: A Single Center Cross-sectional Study*
por: Martin Bagos, John Paul, et al.
Publicado: (2023)

Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment
por: Mohan, Viswanathan, et al.
Publicado: (2019)

Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting
por: Kaur, Parjeet, et al.
Publicado: (2016)

Vitamin D in COVID - 19: Dousing the fire or averting the storm? – A perspective from the Asia-Pacific
por: Chandran, Manju, et al.
Publicado: (2020)

Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2021)

Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study
por: Ji, Linong, et al.
Publicado: (2016)

Prevalence and Associated Factors for Thyroid Dysfunction Among Patients On Targeted Therapy for Cancers: A Single-Center Study from Thailand
por: Chawalitmongkol, Korawan, et al.
Publicado: (2023)

A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with Essential Hypertension and Type 2 Diabetes in Asia
por: Deerochanawong, Chaicharn, et al.
Publicado: (2022)

Perceptions of Painful Diabetic Peripheral Neuropathy in South-East Asia: Results from Patient and Physician Surveys
por: Malik, Rayaz A., et al.
Publicado: (2017)

Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2023)

Correction to: Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2023)

Adverse Effect Profile and Effectiveness of Sodium Glucose Co-transporter 2 Inhibitors (SGLT2i) - A Prospective Real-world Setting Study
por: Gill, Harmandeep Kaur, et al.
Publicado: (2019)

Polymorphisms of Aldose Reductase (ALR2) Regulatory Gene are Risk Factors for Diabetic Retinopathy in Type-2 Diabetes Mellitus Patients in Bali, Indonesia
por: Wihandani, Desak Made, et al.
Publicado: (2018)

Vitamin D supplementation in pregnancy
por: Mithal, Ambrish, et al.
Publicado: (2014)

Optimizing Glycemic Control Through Titration of Insulin Glargine 100 U/mL: A Review of Current and Future Approaches with a Focus on Asian Populations
por: Deerochanawong, Chaicharn, et al.
Publicado: (2017)

Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence from a Tertiary Care Diabetes Center in India
por: Wasir, Jasjeet S., et al.
Publicado: (2018)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates
por: John, Mathew, et al.
Publicado: (2016)

SAT-612 An Anti-Idiotype Antibody to T3 Measurements: A Misleading Cause of Inappropriate TSH Secretion
por: Treesaranuwattana, Thitinan, et al.
Publicado: (2019)

Cost–Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand
por: Vareesangthip, Kriengsak, et al.
Publicado: (2022)

Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus
por: Bawa, Tarunika, et al.
Publicado: (2013)

Dietary beliefs and eating patterns influence metabolic health in type 2 diabetes: A clinic-based study in urban North India
por: Colles, Susan L., et al.
Publicado: (2013)

Quality Frameworks for Virtual Care: Expert Panel Recommendations
por: Demaerschalk, Bart M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pmn8u3n9h6ubroprncodkia6ih